E-LIB Suche - Ergebnisse für: Kim, Sang-We

1

Avelumab in Combination With Lorlatinib or Crizotinib in Pa..:

Solomon, Benjamin J. ; Dagogo-Jack, Ibiayi ; Lee, Se-Hoon...
JTO Clinical and Research Reports. 5 (2024) 7 - p. 100685 , 2024

Link: https://doi.org/10.1016/..

2

Impact of Patient Sex on Adverse Events and Unscheduled Uti..:

Choi, Songji ; Seo, Seyoung ; Lee, Ju Hyun...
Cancer Research and Treatment. 56 (2024) 2 - p. 404-413 , 2024

Link: https://doi.org/10.4143/..

3

Lazertinib as a frontline treatment in patients with EGFR-m..:

Chul Cho, Byoung ; Han, Ji-Youn ; Hyeong Lee, Ki...
Lung Cancer. 190 (2024) - p. 107509 , 2024

Link: https://doi.org/10.1016/..

4

Durvalumab in combination with chemoradiotherapy for patien..:

Kim, Dong-Wan ; Chul Cho, Byoung ; Pachipala, Krishna...
Lung Cancer. 190 (2024) - p. 107530 , 2024

Link: https://doi.org/10.1016/..

5

Biomarker-directed targeted therapy plus durvalumab in adva..:

Besse, Benjamin ; Pons-Tostivint, Elvire ; Park, Keunchil...
Nature Medicine. 30 (2024) 3 - p. 716-729 , 2024

Link: https://doi.org/10.1038/..

6

Alectinib Versus Crizotinib in Asian Patients With Treatmen..:

Zhou, Caicun ; Lu, You ; Kim, Sang-We...
JTO Clinical and Research Reports. , 2024

Link: https://doi.org/10.1016/..

7

Lazertinib versus Gefitinib as First-Line Treatment for EGF..:

Lee, Ki Hyeong ; Cho, Byoung Chul ; Ahn, Myung-Ju...
Cancer Research and Treatment. 56 (2024) 1 - p. 48-60 , 2024

Link: https://doi.org/10.4143/..

8

A Brief Report of Durvalumab With or Without Tremelimumab i..:

Garon, Edward B. ; Cho, Byoung Chul ; Luft, Alexander...
Clinical Lung Cancer. 25 (2024) 3 - p. 266-273.e5 , 2024

Link: https://doi.org/10.1016/..

9

First-in-human study of oleclumab, a potent, selective anti..:

Bendell, Johanna ; LoRusso, Patricia ; Overman, Michael...
Cancer Immunology, Immunotherapy. 72 (2023) 7 - p. 2443-2458 , 2023

Link: https://doi.org/10.1007/..

10

Integrative analysis of risk factors for immune-related adv..:

Sung, Changhwan ; An, Jinhyeon ; Lee, Soohyeon...
Nature Cancer. 4 (2023) 6 - p. 844-859 , 2023

Link: https://doi.org/10.1038/..

11

PP382 EGFR and HER2 exon 20 insertion mutations in non-smal..:

Lee, So Heun ; Jeong, Hyehyun ; Kim, Deok Hoon...
ESMO Open. 8 (2023) 1 - p. 102175 , 2023

Link: https://doi.org/10.1016/..

12

Systemic and Intracranial Outcomes With First-Line Nivoluma..:

Reck, Martin ; Ciuleanu, Tudor-Eliade ; Lee, Jong-Seok...
Journal of Thoracic Oncology. 18 (2023) 8 - p. 1055-1069 , 2023

Link: https://doi.org/10.1016/..

13

Sotorasib versus docetaxel for previously treated non-small..:

de Langen, Adrianus Johannes ; Johnson, Melissa L ; Mazieres, Julien...
The Lancet. 401 (2023) 10378 - p. 733-746 , 2023

Link: https://doi.org/10.1016/..

14

Olaparib and durvalumab in patients with relapsed small cel..:

Krebs, Matthew G. ; Delord, Jean-Pierre ; Jeffry Evans, Thomas R....
Lung Cancer. 180 (2023) - p. 107216 , 2023

Link: https://doi.org/10.1016/..

15

Patient-reported outcomes with durvalumab, with or without ..:

Garon, Edward B. ; Cho, Byoung Chul ; Luft, Alexander...
Lung Cancer. 186 (2023) - p. 107422 , 2023

Link: https://doi.org/10.1016/..